Cullinan Therapeutics Business Update
Cullinan Therapeutics has initiated a rolling New Drug Application (NDA) submission to the FDA for zipalertinib in combination with chemotherapy for first-line treatment of NSCLC with EGFR exon 20 insertion mutations. The submission is being conducted under the FDA's Real-Time Oncology Review (RTOR) program and is supported by positive Phase 3 REZILIENT3 trial data. Completion of the submission is expected by year-end 2026, potentially triggering a $100 million milestone payment from partner Taiho upon approval.
- Counterparty
- FDA